stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) EPS (diluted)
Natera, Inc.'s EPS (diluted) for fiscal 2025 was −$1.52, compared with −$1.53 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.14. Over the past ten years it has ranged from −$5.57 (fiscal 2022) to −$1.52 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. Natera, Inc. ranks 33rd of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.52 | — |
| FY2024 | −$1.53 | — |
| FY2023 | −$3.78 | — |
| FY2022 | −$5.57 | — |
| FY2021 | −$5.21 | — |
| FY2020 | −$2.84 | — |
| FY2019 | −$1.79 | — |
| FY2018 | −$2.22 | — |
| FY2017 | −$2.56 | — |
| FY2016 | −$1.86 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.42 | — |
| Jun 2026 | −$0.47 | — |
| Mar 2026 | −$0.60 | — |
| Dec 2025 | $0.35 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| IDXX IDEXX Laboratories, Inc. compare | $14.83 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| IQV IQVIA Holdings Inc. compare | $8.24 |
| ILMN Illumina, Inc. compare | $5.81 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation compare | $2.33 |
| NTRA Natera, Inc. | −$1.14 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NTRA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement